Patents by Inventor John Rounds

John Rounds has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and Methods Related to Multimodal Therapeutic Cell Systems for Cancer Indications
    Publication number: 20230293588
    Abstract: The invention includes compositions and methods related to multimodal therapies, e.g., for treating a cancer. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having a cancer.
    Type: Application
    Filed: January 25, 2023
    Publication date: September 21, 2023
    Applicant: Rubius Therapeutics, Inc.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Robert J. Deans, Tiffany F. Chen, John Round, Noubar B. Afeyan, Torben Straight Nissen, Nathan J. Dowden, Tom Wickham, Sivan Elloul
  • Methods and compositions for immunomodulation
    Patent number: 11576934
    Abstract: Provided are cells containing exogenous antigen and uses thereof.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: February 14, 2023
    Assignee: Rubius Therapeutics, Inc.
    Inventors: Jordi Mata-Fink, John Round, Noubar B. Afeyan, Avak Kahvejian
  • Methods and compositions for immunomodulation
    Patent number: 11554141
    Abstract: Provided are cells containing exogenous antigen and uses thereof.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: January 17, 2023
    Assignee: Rubius Therapeutics, Inc.
    Inventors: Jordi Mata-Fink, John Round, Noubar B. Afeyan, Avak Kahvejian
  • Compositions and Methods Related to Multimodal Therapeutic Cell Systems for Autoimmune Indications
    Publication number: 20220072048
    Abstract: The invention includes compositions and methods related to multimodal therapies, e.g., for treating immune conditions. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having an autoimmune disease or inflammatory disease.
    Type: Application
    Filed: November 17, 2021
    Publication date: March 10, 2022
    Applicant: Rubius Therapeutics, Inc.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Robert J. Deans, Tiffany F. Chen, John Round, Noubar B. Afeyan, Torben Straight Nissen, Nathan Dowden, Tom Wickham
  • Methods and compositions for immunomodulation
    Patent number: 10869898
    Abstract: Provided are cells containing exogenous antigen and uses thereof.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: December 22, 2020
    Assignee: Rubius Therapeutics, Inc.
    Inventors: Jordi Mata-Fink, John Round, Noubar B. Afeyan, Avak Kahvejian
  • Compositions and methods related to multimodal therapeutic cancer indications
    Patent number: 10716811
    Abstract: The invention includes compositions and methods related to multimodal therapies, e.g., for treating a cancer. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having a cancer.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: July 21, 2020
    Assignee: Rubius Therapeutics Inc.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Robert J. Deans, Tiffany F. Chen, John Round, Noubar B. Afeyan, Torben Straight Nissen, Nathan Dowden, Tom Wickham, Sivan Elloul
  • COMPOSITIONS AND METHODS RELATED TO MULTIMODAL THERAPEUTIC CELL SYSTEMS FOR INFECTIOUS DISEASE
    Publication number: 20200172868
    Abstract: The invention includes compositions and methods related to multimodal therapies, e.g., for treating an infectious disease. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having an infectious disease.
    Type: Application
    Filed: July 19, 2017
    Publication date: June 4, 2020
    Inventors: Tom Wickham, Tiffany F. Chen, Nathan Dowden, Robert Finberg, Robert J. Deans, John Round, Avak Kahvejian, Jordi Mata-Fink, Noubar B. Afeyan
  • COMPOSITIONS AND METHODS RELATED TO MULTIMODAL THERAPEUTIC CELL SYSTEMS FOR CARDIOMETABOLIC DISEASE
    Publication number: 20200172867
    Abstract: The invention includes compositions and methods related to multimodal therapies, e.g., for treating cardiovascular diseases and metabolic disorders. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having a cardiovascular disease or metabolic disorder.
    Type: Application
    Filed: July 19, 2017
    Publication date: June 4, 2020
    Inventors: Tom Wickham, Tiffany F. Chen, Torben Straight Nissen, Nathan Dowden, Robert J. Deans, John Round, Avak Kahvejian, Jordi Mata-Fink, Noubar B. Afeyan
  • COMPOSITIONS AND METHODS RELATED TO ENGINEERED ERYTHROID CELLS COMPRISING IL-15
    Publication number: 20200129556
    Abstract: The invention includes compositions and methods related to multimodal therapies, e.g., for treating a cancer. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having a cancer.
    Type: Application
    Filed: January 8, 2020
    Publication date: April 30, 2020
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Robert J. Deans, Tiffany F. Chen, John Round, Noubar B. Afeyan, Torben Straight Nissen, Nathan Dowden, Tom Wickham, Sivan Elloul
  • Compositions and methods related to engineered erythroid cells comprising IL-15
    Patent number: 10568910
    Abstract: The invention includes compositions and methods related to multimodal therapies, e.g., for treating a cancer. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having a cancer.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: February 25, 2020
    Assignee: RUBIUS THERAPEUTICS, INC.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Robert J. Deans, Tiffany F. Chen, John Round, Noubar B. Afeyan, Torben Straight Nissen, Nathan Dowden, Tom Wickham, Sivan Elloul
  • Erythroid cells comprising phenylalanine ammonia lyase
    Patent number: 10557119
    Abstract: Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: February 11, 2020
    Assignee: RUBIUS THERAPEUTICS, INC.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, John Round, David Arthur Berry, Noubar B. Afeyan
  • METHODS RELATED TO ENGINEERED ERYTHOID CELLS COMPRISING 4-1BBL
    Publication number: 20200016209
    Abstract: The invention includes compositions and methods related to multimodal therapies, e.g., for treating a cancer. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having a cancer.
    Type: Application
    Filed: September 18, 2019
    Publication date: January 16, 2020
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Robert J. Deans, Tiffany F. Chen, John Round, Noubar B. Afeyan, Torben Straight Nissen, Nathan Dowden, Tom Wickham, Sivan Elloul
  • ERYTHROID CELLS COMPRISING PHENYLALANINE HYDROXYLASE
    Publication number: 20200002674
    Abstract: Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.
    Type: Application
    Filed: September 16, 2019
    Publication date: January 2, 2020
    Inventors: Avak Kahvejian, Jordi Mata-Fink, John Round, David Arthur Berry, Noubar B. Afeyan
  • Methods related to engineered erythoid cells comprising 4-1BBL
    Patent number: 10517897
    Abstract: The invention includes compositions and methods related to multimodal therapies, e.g., for treating a cancer. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having a cancer.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: December 31, 2019
    Assignee: RUBIUS THERAPEUTICS, INC.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Robert J. Deans, Tiffany F. Chen, John Round, Noubar B. Afeyan, Torben Straight Nissen, Nathan Dowden, Tom Wickham, Sivan Elloul
  • METHODS AND COMPOSITIONS FOR IMMUNOMODULATION
    Publication number: 20190388473
    Abstract: Provided are cells containing exogenous antigen and uses thereof.
    Type: Application
    Filed: August 30, 2019
    Publication date: December 26, 2019
    Inventors: Jordi Mata-Fink, John Round, Noubar B. Afeyan, Avak Kahvejian
  • PLATELETS COMPRISING EXOGENOUS POLYPEPTIDES AND USES THEREOF
    Publication number: 20190376034
    Abstract: Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.
    Type: Application
    Filed: August 23, 2019
    Publication date: December 12, 2019
    Inventors: Avak Kahvejian, Jordi Mata-Fink, John Round, David Arthur Berry, Noubar B. Afeyan
  • Compositions and methods related to engineered erythoid cells comprising 4-1BBL
    Patent number: 10456421
    Abstract: The invention includes compositions and methods related to multimodal therapies, e.g., for treating a cancer. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having a cancer.
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: October 29, 2019
    Assignee: RUBIUS THERAPEUTICS, INC.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Robert J. Deans, Tiffany F. Chen, John Round, Noubar B. Afeyan, Torben Straight Nissen, Nathan Dowden, Tom Wickham, Sivan Elloul
  • ERYTHROID CELLS COMPRISING ARGINASE
    Publication number: 20190316091
    Abstract: Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.
    Type: Application
    Filed: May 30, 2019
    Publication date: October 17, 2019
    Inventors: Avak Kahvejian, Jordi Mata-Fink, John Round, David Arthur Berry, Noubar B. Afeyan
  • SYNTHETIC MEMBRANE-RECEIVER COMPLEXES
    Publication number: 20190316089
    Abstract: Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.
    Type: Application
    Filed: May 10, 2019
    Publication date: October 17, 2019
    Inventors: Avak Kahvejian, Jordi Mata-Fink, John Round, David Arthur Berry, Noubar B. Afeyan
  • ERYTHROID CELLS COMPRISING ARGININE DEIMINASE
    Publication number: 20190316090
    Abstract: Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.
    Type: Application
    Filed: May 30, 2019
    Publication date: October 17, 2019
    Applicants: RUBIUS THERAPEUTICS, INC., RUBIUS THERAPEUTICS, INC.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, John Round, David Arthur Berry, Noubar B. Afeyan